What is the Next Step – A Black Box Warning or Ban the Drug?
The recent medical literature has been inundated with case reports and population studies linking bisphosphonate drugs to atypical mid-femur fractures, and their associated stress fractures. The message is fairly obvious that there is something dreadfully wrong here. When we have a drug that causes the same disease it is intended to prevent, we have the “perfect storm”. Drug manufacturers use ghost-writers and manipulate the clinical trials to make the drug look good, and clinicians can deny the obvious when patients come in with fractures while on the drug, blaming it on the osteoporosis, and not an adverse effect of the drug. My prediction is that most educated patients and doctors will abandon this family of osteoporosis drugs, and the FDA will eventually issue a Black Box Warning if not a complete ban. Articles with Related Content : Fosamax Whitewash Unconvincing Fosamax and Fractured Femurs Fosamax Induced Bilateral Femur Fractures Fosamax, a Bad Drug in Litigation Bisphosphonate
